Join Growin Stock Community!

Lucid diagnostics inc.LUCD.US Overview

US StockHealthcare
(No presentation for LUCD)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

LUCD AI Insights

LUCD Overall Performance

LUCD AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

LUCD Recent Performance

-2.82%

Lucid diagnostics inc.

0.05%

Avg of Sector

-0.31%

S&P500

LUCD PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

LUCD Key Information

LUCD Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

LUCD Profile

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Price of LUCD

LUCD FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

LUCD Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.52
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
42.91
PB Ratio
2.16
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-58.13%
Net Margin
-1211.30%
Revenue Growth (YoY)
5.01%
Profit Growth (YoY)
-15.08%
3-Year Revenue Growth
151.64%
3-Year Profit Growth
28.71%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.52
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
42.91
PB Ratio
2.16
Price-to-FCF
-
Gross Margin
-58.13%
Net Margin
-1211.30%
Revenue Growth (YoY)
5.01%
Profit Growth (YoY)
-15.08%
3-Year Revenue Growth
151.64%
3-Year Profit Growth
28.71%
  • When is LUCD's latest earnings report released?

    The most recent financial report for Lucid diagnostics inc. (LUCD) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating LUCD's short-term business performance and financial health. For the latest updates on LUCD's earnings releases, visit this page regularly.

  • What is the operating profit of LUCD?

    According to the latest financial report, Lucid diagnostics inc. (LUCD) reported an Operating Profit of -11.76M with an Operating Margin of -971.02% this period, representing a decline of 0.56% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is LUCD's revenue growth?

    In the latest financial report, Lucid diagnostics inc. (LUCD) announced revenue of 1.21M, with a Year-Over-Year growth rate of 3.33%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does LUCD have?

    As of the end of the reporting period, Lucid diagnostics inc. (LUCD) had total debt of 24.34M, with a debt ratio of 0.46. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does LUCD have?

    At the end of the period, Lucid diagnostics inc. (LUCD) held Total Cash and Cash Equivalents of 47.33M, accounting for 0.89 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does LUCD go with three margins increasing?

    In the latest report, Lucid diagnostics inc. (LUCD) did not achieve the “three margins increasing” benchmark, with a gross margin of -40.1%%, operating margin of -971.02%%, and net margin of -858.5%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess LUCD's profit trajectory and future growth potential.

  • Is LUCD's EPS continuing to grow?

    According to the past four quarterly reports, Lucid diagnostics inc. (LUCD)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.1. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of LUCD?

    Lucid diagnostics inc. (LUCD)'s Free Cash Flow (FCF) for the period is -10.92M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 7.33% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.